A biotechnology startup with an FDA approved personalized cell treatment to combat wrinkles around the smile line is advancing its treatment for burn victims with a Phase 2 clinical trial.
Exton, Pennsylvania-based Fibrocell Science’s Azficel-T treatment is designed to to ease the pain and improve the mobility of patients with restrictive burn scars, according to a company statement. The study, scheduled for the first quarter of 2013, will enroll 20 subjects who have unilateral restrictive burn scars around elbows, shoulders, fingers and other jointed areas. It will assess range of motion, brief pain index and scar appearance.
The Phase 2 study announcement follows a major strategic financing round in October in which Fibrocell raised $45 million through a private stock sale to help advance its treatments for acne and burn victims through clinical studies. It also embarked on a collaboration with synthetic biology company Intrexon Corp., a synthetic biology company that develops technologies to control cellular functions.
Immune Support on Demand: Ranking the Top Mobile IV Therapy Companies
Explore the top mobile IV therapy companies boosting immune health on demand, with standout services, expert care and innovative delivery across the U.S.
Firbocell’s treatment uses fibroblasts, which play a critical role in wound healing. The company’s personalized cell development platform technology isolates, purifies and multiplies a patient’s fibroblast cells — connective skin cells that make collagen.
Severe burns affect an estimated 45,000 people each year, according to data from the American Burn Association.
[Photo from from flickr user wwarby]